Clinical Trial Update: 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating 177Lu-PSMA-617 with Niraparib and abiraterone acetate plus prednisone for metastatic prostate cancer and castration-resistant prost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)
• Niraparib (Zejula) (Niraparib)
• PREDNISONE (Prednisone)
• Pluvicto (Lutetium-177-PSMA-617) (Lutetium-177-PSMA-617)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: WITHDRAWN